The stock’s swings were almost enough to quicken the pulse: The FDA on Tuesday approved a heart pump from HeartWare International Inc., of Framingham, for patients awaiting a heart transplant, and the shares rose 9 percent, the most in seven months. But on Wednesday, the stock fell nearly 9 percent. Similar ventricular assist devices have been approved previously, but HeartWare’s device is smaller and may be easier to implant. The pumps are intended to take over for a failing heart, extending patients’ lives or gaining time to find a heart donor.
HeartWare’s big gain is erased
You have reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week